Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)
Part of paid clinical trials in La Jolla, California.
- Sponsor
- University of California, San Diego
- Study ID
- NCT06482268
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- PD - Parkinson's Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001) — COMBINATION_PRODUCTInvestigational PET agents will be synthesized at UCSD and administered to subjects according to the local institutional guidelines. IND applications for these agents are linked with the IND application for the study product, CT1-DAP001. The IND applications for the PET radiopharmaceuticals contains the manufacturing method, specifications, quality testing, clinical usage, and safety and efficacy information for individual PET agents. Investigational Cell Injector Suniviion needle: The investigational instrument will be used to administer dopaminergic progenitors into the putamen. After aspirating cells, the instrument will be attached to a Leksell stereotactic frame to administer the cells into the brain.
Study Details
To evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
Key Dates
- Start date
- Jun 1, 2024
- Status verified
- Jan 2025
- Primary completion
- Feb 28, 2025
- Completion
- May 31, 2028
Study Design
- Enrollment
- 7 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Other: Single-center, open-label, uncontrolledTo evaluate the safety and efficacy of transplantation of human induced pluripotent stem cell-derived dopaminergic progenitors, CT1-DAP001, into the corpus striatum in patients with Parkinson's disease
Primary Outcome Measure
ACCEPTABILITY [ Time Frame: 24 months ]
Central Contacts
- Christian Fulinara(858) 2494020
- Donna Brusch(760) 505-6649
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of California, San Diego | La Jolla | California | 92037 | Joseph Ciacci, MD (PRINCIPAL_INVESTIGATOR) Sharona Ben-Haim, MD (SUB_INVESTIGATOR) Stephanie Lessig, MD (SUB_INVESTIGATOR) Forseth Kiefer, MD (SUB_INVESTIGATOR) Marsala Martin, MD (SUB_INVESTIGATOR) |
Find similar trials in La Jolla, CA
By research site
Related Studies
- Simplified, Scalable, 24-hour Adaptive DBS in Parkinson's DiseaseRecruiting · University of California, San Francisco · San Francisco, California